1. Home
  2. CDIO vs LCFY Comparison

CDIO vs LCFY Comparison

Compare CDIO & LCFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDIO
  • LCFY
  • Stock Information
  • Founded
  • CDIO 2017
  • LCFY 2009
  • Country
  • CDIO United States
  • LCFY Australia
  • Employees
  • CDIO N/A
  • LCFY N/A
  • Industry
  • CDIO Biotechnology: Commercial Physical & Biological Resarch
  • LCFY
  • Sector
  • CDIO Health Care
  • LCFY
  • Exchange
  • CDIO Nasdaq
  • LCFY Nasdaq
  • Market Cap
  • CDIO 8.0M
  • LCFY 9.2M
  • IPO Year
  • CDIO N/A
  • LCFY 2022
  • Fundamental
  • Price
  • CDIO $4.23
  • LCFY $5.18
  • Analyst Decision
  • CDIO
  • LCFY
  • Analyst Count
  • CDIO 0
  • LCFY 0
  • Target Price
  • CDIO N/A
  • LCFY N/A
  • AVG Volume (30 Days)
  • CDIO 47.5K
  • LCFY 118.8K
  • Earning Date
  • CDIO 11-12-2025
  • LCFY 11-11-2025
  • Dividend Yield
  • CDIO N/A
  • LCFY N/A
  • EPS Growth
  • CDIO N/A
  • LCFY N/A
  • EPS
  • CDIO N/A
  • LCFY N/A
  • Revenue
  • CDIO $19,507.00
  • LCFY $2,231,313.00
  • Revenue This Year
  • CDIO $1,434.82
  • LCFY N/A
  • Revenue Next Year
  • CDIO $4,661.91
  • LCFY N/A
  • P/E Ratio
  • CDIO N/A
  • LCFY N/A
  • Revenue Growth
  • CDIO N/A
  • LCFY N/A
  • 52 Week Low
  • CDIO $3.22
  • LCFY $2.51
  • 52 Week High
  • CDIO $53.10
  • LCFY $13.98
  • Technical
  • Relative Strength Index (RSI)
  • CDIO 50.58
  • LCFY 38.53
  • Support Level
  • CDIO $4.03
  • LCFY $5.03
  • Resistance Level
  • CDIO $4.66
  • LCFY $5.50
  • Average True Range (ATR)
  • CDIO 0.35
  • LCFY 0.64
  • MACD
  • CDIO -0.01
  • LCFY -0.23
  • Stochastic Oscillator
  • CDIO 40.38
  • LCFY 31.54

About CDIO Cardio Diagnostics Holdings Inc. Common stock

Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.

About LCFY Locafy Limited

Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has two operating segments: Publishing and SEO agency. Under the Publishing segment are products and services that the Company offers that are related to digital properties (i.e. mastheads) that it owns e.g. business data published on Hotfrog, advertising placed on AussieWeb, articles published on scoop.com.au. In contrast, under the SEO Agency segment are products and services that are applied to digital properties that are owned and operated by third parties. It derives a majority of its revenue in North America from SEO Agency.

Share on Social Networks: